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Abstract
Background: Most genetic disorders are linked to missense mutations as even minor changes in
the size or properties of an amino acid can alter or prevent the function of the protein. Further,
the effect of a mutation is also dependent on the sequence and structure context of the alteration.
Results:  We investigated the spectrum of disease-causing missense mutations in secondary
structure elements in proteins with numerous known mutations and for which an experimentally
defined three-dimensional structure is available. We obtained a comprehensive map of the
differences in mutation frequencies, location and contact energies, and the changes in residue
volume and charge – both in the mutated (original) amino acids and in the mutant amino acids in
the different secondary structure types. We collected information for 44 different proteins
involved in a large number of diseases. The studied proteins contained a total of 2413 mutations of
which 1935 (80%) appeared in secondary structures. Differences in mutation patterns between
secondary structures and whole proteins were generally not statistically significant whereas within
the secondary structural elements numerous highly significant features were observed.
Conclusion: Numerous trends in mutated and mutant amino acids are apparent. Among the
original residues, arginine clearly has the highest relative mutability. The overall relative mutability
among mutant residues is highest for cysteine and tryptophan. The mutability values are higher for
mutated residues than for mutant residues. Arginine and glycine are among the most mutated
residues in all secondary structures whereas the other amino acids have large variations in
mutability between structure types. Statistical analysis was used to reveal trends in different
secondary structural elements, residue types as well as for the charge and volume changes.
Background
Now that the sequence of the human genome is almost
complete, the research interest in genomics has moved
from determining the sequence to the analysis of genetic
variations, e.g. the Human Variome Project [1], and col-
lecting data in locus-specific mutation databases [2,3].
There is also a race to develop methods for cost-effective
sequencing of the genomes of individuals [4]. Missense
mutations in coding DNA, which lead to single amino
acid changes in proteins, are commonly linked to human
disorders [5]. The number of documented disease-linked
missense and nonsense mutations is close to 30,000 [6].
A disease phenotype can arise because an amino acid
change results in the loss of a critical protein function, in
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structural alterations, or because the mutation leads to
"gain of function" effects such as functional dysregulation
or the formation of toxic aggregates [7-9].
Only correctly folded proteins can deliver all the func-
tional properties of a protein. Even minor changes in the
size or properties of an amino acid side chain can alter or
prevent the function of the protein. On the other hand,
even large deletions or insertions may be tolerated in
numerous positions within a protein [10]. The effects of
mutations are also dependent on the protein sequence
and structure context of the alteration. General statistical
analyses have been performed for disease-causing muta-
tions, for non-synonymous SNPs (nsSNPs) [9,11-16], for
groups of diseases, such as immunodeficiencies [3], and
for groups of proteins, such as protein kinases [17]. Based
on these studies and others, a number of methods have
been developed for the prediction of tolerance and the
consequences of mutations [13,18-23].
Structural information is needed to fully understand the
effects and consequences of mutations, whether disease-
causing or used purposefully to modify the properties of a
protein e.g. in protein engineering. Three-dimensional
structures and computer models have been used by us and
others to elucidate disease mechanisms from amino acid
substitutions e.g. in references [24-26]. We have reviewed
and discussed the applicability of more than 30 sequence
and structure utilizing methods to predict the outcome of
missense mutations to explain the basis of diseases [27].
Activity modifying mutations are also valuable for under-
standing the functions and conservation of amino acids
and sequence regions in protein families. Recently, all the
possible amino acid substitutions and their effects on bio-
physical properties were investigated in five proteins [28].
Secondary structural elements, α-helices, β-strands, turns
and bends, are basic structural components of protein
scaffolds. Amino acids are differently distributed between
these elements. This information has been utilized for
decades to predict the location of secondary structures
from sequence information e.g. in references [29-34]. Sec-
ondary structures are common regular conformations of
polypeptides, and they are the most energetically favoura-
ble structures. Each secondary structure type has character-
istic backbone φ and ψ angles. Secondary structures fold
together in proteins and form higher order structures such
as super secondary structures, motifs, domains and terti-
ary structures. The organization of the folds is very similar
in related protein structures even though the sequence
identities can be very small. Secondary structures are gen-
erally of substantial length and can pass through the
hydrophobic core of globular proteins. Within protein
families the secondary structures are more conserved than
the surface loops connecting the adjacent elements.
Since secondary structures are structural building blocks
that cover some 25 – 75% of the length of proteins, it
would be interesting to know how disease-related, and
thus function and/or structure altering, mutations affect
these elements. We investigated the occurrence, location
and distribution of disease-causing mutations in second-
ary structures. The study is based on statistics and bioin-
formatical analysis of three-dimensional structures and
protein sequence information. Not many differences
occur in mutation types between secondary structure ele-
ments and whole proteins. Clear differences were
observed within the mutation spectra for different second-
ary structural elements and regions outside secondary
structures. Some features, like the overrepresentation of
arginines, were evident in all the secondary structures.
Our analysis covers different amino acid substitutions,
alterations of physicochemical properties, and sequence
conservation. We investigated mutations both in the
mutated original residues and in the mutant, altered,
amino acids.
Results and discussion
Secondary structures have an energetically favourable
organization of the polypeptide chain. Our aim was to
obtain a comprehensive map of the differences in muta-
tion frequencies, location, contact energies and changes in
residue volume and charge, both in the mutated amino
acids and in the mutant amino acids, for the different sec-
ondary structure types. We collected information for 44
proteins involved in a large number of diseases (Table 1).
The criteria for choosing the proteins were a relatively
large number of reported missense mutations and the
availability of the three-dimensional structure. The genes
in Table 1 are listed with the recommended HGNC names
(HUGO Gene Nomenclature Committee) [35,36]. The
number of missense mutations varied from 8 to 240 per
investigated protein or domain. The proteins represent
different activities and functions including enzymes, sig-
nalling proteins, membrane proteins, receptors etc. 42 of
the total of 46 structures had a resolution greater than
2.00 Å. There are more PDB entries than proteins because
for the large BTK and VDR proteins there are two struc-
tures for different domains. The studied proteins con-
tained altogether 2413 mutations of which 1935 (80%)
appeared in secondary structures. The amino acid compo-
sition of all the proteins is in Figure 1. Considering the
large size of the dataset and diversity of protein types and
functions the statistically significant results reveal the true
nature of disease-causing amino acid changes. In the χ2-
test, results were considered significant with a P value <
0.05.
The total chain length of the 44 investigated proteins is
12540 amino acids. The secondary structure elements
consist as follows: all helix structures altogether 4567BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Table 1: Summary of analysed proteins and diseases
Name Symbol PDB OMIM Disease(s) Mutations
ABO blood group (transferase 
A, α1–3-N-
acetylgalactosaminyltransferas
e; transferase B, α1–3-
galactosyltransferase)
ABO 1lzj 110300 Blood group variation 22
alanine-glyoxylate 
aminotransferase (oxalosis I; 
hyperoxaluria I; 
glycolicaciduria; serine-
pyruvate aminotransferase)
AGXT 1h0c 604285 Hyperoxaluria 22
arylsulfatase B ARSB 1fsu 253200 Mucopolysaccharidosis VI 30
argininosuccinate lyase ASL 1k62 608310 Argininosuccinate lyase deficiency 21
Bruton agammaglobulinemia 
tyrosine kinase
BTK 1btk, 1k2p 300300 X-linked agammaglobulinaemia 144
cystathionine-β-synthase CBS 1jbq 236200 Homocystinuria 74
CD40 ligand (TNF 
superfamily, member 5, 
hyper-IgM syndrome)
CD40LG 1aly 300386 Hyper-IgM syndrome 27
cystic fibrosis transmembrane 
conductance regulator, ATP-
binding cassette (sub-family C, 
member 7)
CFTR 1xmj 602421 Asthma; Cystic fibrosis; Idiopathic pancreatitis; Congenital 
absence of vas deferens; Hereditary pancreatitis; 
Hypertrypsinaemia; Primary sclerosing cholangitis; Susceptibility 
to sarcoidosis; Idiopathic Bronchiectasis
86
CHK2 checkpoint homolog CHEK2 1gxc 604373 Multiple cancers 10
doublecortex; lissencephaly, 
X-linked (doublecortin)
DCX 1mjd 300121 Double cortex syndrome; X linked lissencephaly syndrome; 
Subcortical band heterotopia; Resistant partial seizures
16
cytochrome b5 reductase 3 CYB5R3 1umk 250800 Methaemoglobinaemia 18
ectodysplasin A EDA 1rj7 300451 Ectodermal dysplasia 22
coagulation factor XIII, A1 
polypeptide
F13A1 1f13 134570 Factor XIII deficiency 30
coagulation factor VIII, 
procoagulant component 
(hemophilia A)
F8 1iqd 306700 Haemophilia A 39
glucose-6-phosphate 
dehydrogenase
G6PD 1qki 305900 Glucose-6-phosphate dehydrogenase deficiency 130
GTP cyclohydrolase 1 (dopa-
responsive dystonia)
GCH1 1fb1 600225 Dopa-responsive and progressive dystonia; 
Tetrahydrobiopterin deficiency
45
galactosidase, α GLA 1r46 301500 Fabry disease 179
glucuronidase, β GUSB 1bhg 253220 Mucopolysaccharidosis VII; Hydrops fetalis 28
hemoglobin, β HBB 1o1p 141900 Haemoglobin variant; Haemolytic anaemia; β-thalassaemia; 
Erythrocytosis; Sickle cell anaemia
160
homogentisate 1,2-
dioxygenase (homogentisate 
oxidase)
HGD 1eyb 607474 Alkaptonuria 29
hypoxanthine 
phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome)
HPRT1 1bzy 308000 Hypoxanthine guanine phosphoribosyltransferase deficiency; 
Lesch-Nyhan syndrome; Hyperuricaemia; Hyperuricaemia with 
neurologic symptoms
105
insulin receptor INSR 1ir3 147670 Leprechaunism; Insulin resistance; Insulin resistance A; 
Association with reduced diastolic blood pressure; Diabetes, 
NIDDM; Rabson-Mendenhall syndrome
19
lamin A/C LMNA 1ifr 150330 Muscular dystrophy; Emery-Dreifuss; Seip syndrome; Dilated 
cardiomyopathy; Partial lipodystrophy; Atypical Werner 
Syndrome; Familial autosomal dominant partial lipodystrophy 
(Dunnigan variety); Hutchinson-Gilford progeria syndrome; 
Charcot-Marie-Tooth disease 2; Cardiac conduction defects; 
Muscular dystrophy; Partial lipodystrophy; Mandibuloacral 
dysplasia; Association with metabolic syndrome
22
neurofibromin 2 (bilateral 
acoustic neuroma)
NF2 1h4r 607379 Neurofibromatosis 2 8
ornithine aminotransferase 
(gyrate atrophy)
OAT 2oat 258870 Gyrate atrophy 27
ornithine 
carbamoyltransferase
OTC 1oth 300461 Ornithine transcarbamylase deficiency; Hyperammonaemia 154
phenylalanine hydroxylase PAH 1j8u 261600 Phenylketonuria; Hyperphenylalaninaemia 240BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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paired box gene 6 (aniridia, 
keratitis)
PAX6 6pax 607108 Aniridia; Congenital cataract; Peters' anomaly; Optic-nerve 
malformations; Congenital nystagmus; Ectopia pupillae; Isolated 
foveal hypoplasia; Ocular anterior segment anomaly
27
pyruvate dehydrogenase 
(lipoamide) α1
PDHA1 1ni4 300502 Pyruvate dehydrogenase deficiency; Lactic acidosis; Leigh 
syndrome
40
pyruvate kinase, liver and RBC PKLR 1liu 266200 Elevated red cell ATP; Haemolytic anaemia; Pyruvate kinase 
deficiency
93
prion protein (p27–30) 
(Creutzfeldt-Jakob disease, 
Gerstmann-Strausler-
Scheinker syndrome, fatal 
familial insomnia)
PRNP 1i4m 176640 Gerstmann-Straussler-Scheinker syndrome; Dementia; 
Creutzfeld-Jakob syndrome; Schizophrenia; Familial spongiform 
encephalopathy; Fatal familial insomnia; Prion disease
23
retinoblastoma 1 (including 
osteosarcoma)
RB1 1gux 180200 Retinoblastoma 18
solute carrier family 4, anion 
exchanger, member 1 
(erythrocyte membrane 
protein band 3, Diego blood 
group)
SLC4A1 1hyn 109270 Spherocytosis; Blood group variation; Erythrocyte band 3 
deficiency; Anaemia; Distal renal tubular acidosis; 
Acanthocytosis
7
superoxide dismutase 1, 
soluble (amyotrophic lateral 
sclerosis 1 (adult))
SOD1 1mfm 147450 Amyotrophic lateral sclerosis; Motor neuron disease 69
sex determining region Y SRY 1j46 480000 XY sex reversal; Gonadal dysgenesis; Hermaphroditism 31
transcription factor 1, hepatic; 
LF-B1, hepatic nuclear factor 
(HNF1), albumin proximal 
factor
TCF1 1ic8 142410 Diabetes mellitus, type 2; MODY; MODY2; MODY3; Serum C-
peptide and insulin response; Insulin resistance
40
thyroid hormone receptor, β 
thyroid hormone receptor, 
beta (erythroblastic leukemia 
viral (v-erb-a) oncogene 
homolog 2, avian)
THRB 1nq2 190160 Thyroid hormone resistance 72
troponin T type 2 (cardiac) TNNT2 1j1d 191045 hypertrophic/dilated cardiomyopathy 4
troponin I type 3 (cardiac) TNNI3 1j1e 191044 hypertrophic/restrictive cardiomyopathy 7
tumor protein p53 (Li-
Fraumeni syndrome)
TP53 1tup 191170 Li-Fraumeni syndrome; Adrenocortical carcinoma; Sarcoma; 
Lung cancer; Breast cancer; Carcinoma; Glioma; Astrocytoma; 
Adrenocortical carcinoma; Glioblastoma; Cytosarcoma 
phyllodes; Osteosarcoma; Multiple cancers; Familial 
adenomatous polyposis; Rhabdomyosarcoma; Ependymoma; 
Adenocarcinoma; Thyroid tumour; Leukaemia/lymphoma; 
Neuroblastoma
73
uroporphyrinogen 
decarboxylase
UROD 1r3s 176100 Porphyria cutanea tarda; Hepatoerythropoietic porphyria 37
uroporphyrinogen III synthase 
(congenital erythropoietic 
porphyria)
UROS 1jr2 606938 Erythropoietic porphyria; Guenther disease 21
vitamin D (1,25-
dihydroxyvitamin D3) 
receptor
VDR 1ie9, 1kb2 601769 Higher bone mineral density; Rickets 10
von Hippel-Lindau tumor 
suppressor
VHL 1lm8 608537 von Hippel-Lindau syndrome; Phaeochromocytoma; 
Haemangioblastoma; Pancreatic cancer; Polycythemia, with high 
erythropoietin concentration; Phaeochromocytoma and 
paraganglioma
134
Table 1: Summary of analysed proteins and diseases (Continued)
amino acids of which α-helices 4118 (~90%), 310-helices
449 (~10%) and π-helices just 2 residues. There are 153
amino acids in β-bridges and 2530 in β-ladders, alto-
gether 2683 (27%), and there are 1436 (15%) and 1190
(12%) residues in turns and bends, respectively. 18 pro-
teins belong to SCOP [37] class for all-α proteins, 12 pro-
teins belong to all-β proteins, 22 proteins belong to α and
β proteins (14 α/β and 8 α+β) and 2 to coiled coil pro-
teins. Btk PH domain belongs to all-β proteins and kinase
domain to α+β proteins. In VDR, nuclear receptor ligand-
binding domain belongs to all-α proteins and glucocorti-
coid receptor-like (DNA-binding domain) to SCOP class
for small proteins. Altogether there were 1939 mutations
in the secondary structures, 48% in helices, 28% in β-
structures, and 24% in turns and bends. These numbers
follow the distribution of the structure elements. TheBMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Amino acid distribution and relative mutability Figure 1
Amino acid distribution and relative mutability. Top row. Amino acid distribution in the investigated proteins (left), 
overall relative mutability of mutated (middle) and mutant residues (right). The same information is on the second row only for 
α-helices, third row for β-strands, fourth row for turns and bends, and in the bottom row for structures outside secondary 
structural elements.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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length of the secondary structures varied as follows: α-hel-
ices from 1 to 46 residues, average length being 11.3 resi-
dues, 310-helices from 2 to 9 residues, average 3.4. In β-
strands the length varied from 1 to 22, average 5.28.
Length of the structure in turns varied from 1 to 8 resi-
dues, average 2.1, and in bends from 1 to 6, average 1.6.
Overall amino acid mutational spectrum
Table 2 summarizes all the mutations in the studied pro-
teins and Table 3 mutations in the secondary structures
only. DSSP classifies secondary structures into three helix
types, two extended β-strand types, turns and bends. The
helices represent the classical α-helix,  π-helix and 310-
helix. The difference between the helix types originates
from the number of residues per turn. In the normal right-
handed α-helix there are 3.6 residues per turn, while π-
helix has 4.4, and 310-helix only three. In helical structures
the main chain residues form stabilizing hydrogen bonds
with residues further in the sequence. All the side chains
are pointing out from the helical core. A large proportion
of α-helices are amphipathic i.e. one face of the helix is
hydrophilic and the other hydrophobic [38]. The 310-
helix is the fourth most common type of secondary struc-
ture in proteins after α-helices,  β-strands, and reverse
turns [39]. 310-helices commonly appear as N- or C-termi-
nal extensions of α-helices. They are typically only three
residues long compared with a mean of 10–12 residues
for α-helices [40]. β-Strands are divided into isolated β-
bridges and extended strands. β-Strands can form struc-
ture stabilizing hydrogen bonds only with another strand
in a parallel or antiparallel manner. Bends and turns are,
according to DSSP terminology, relatively short structures
that are located between the helical and strand elements.
Well organized β- and γ-turns reverse the direction of the
polypeptide chain. Only glycines are allowed in certain
turns at certain positions due to steric restrictions in very
tight bends.
First we investigated the statistical significance for
mutated and mutant amino acids located in secondary
structures compared to overall distribution. Then the pat-
terns within each secondary structural element were
revealed.
Arginine is clearly the most mutated residue type, as
already indicated in previous studies [41-43]. The very
high mutability of codons for arginine arises from CpG
dinucleotides, which can spontaneously mutate by deam-
ination either to TG or CA dinucleotides [44]. Arginine is
coded by six codons, four of which have a CpG dinucle-
otide in the first and second codon position. In addition
to the CpG dinucleotide we have also shown previously
that the surrounding sequence context has an effect on
mutability [42].
Table 2: Spectrum of mutations in all residues in the studied proteinsa
Amino 
acid
Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 169 161 0.43 5.14E-01 83 148 28.28*** 1.05E-07
C7 93 843.38*** 4.51E-11 133 86 25.54*** 4.34E-07
D9 81 3 1 8.28** 4.00E-03 155 98 32.54*** 1.16E-08
E1 1 3 1 6 8 17.82*** 2.43E-05 84 86 0.05 8.20E-01
F6 61 0 4 13.66*** 2.19E-04 90 98 0.72 3.97E-01
G2 4 6 1 6 7 37.28*** 1.02E-09 106 141 8.89** 2.87E-03
H8 76 110.74*** 1.05E-03 108 98 0.93 3.34E-01
I9 9 1 2 6 5.76* 1.64E-02 80 129 18.71*** 1.52E-05
K5 61 4 0 50.05*** 1.50E-12 109 86 6.09* 1.36E-02
L 231 239 0.29 5.89E-01 113 203 39.88*** 2.70E-10
M7 8 5 8 7.00** 8.15E-03 97 55 31.33*** 2.18E-08
N 90 92 0.03 8.58E-01 74 98 6.05** 1.39E-02
P9 41 2 2 6.54** 1.05E-02 194 148 14.58*** 1.35E-04
Q6 2 1 0 2 15.50*** 8.24E-05 115 86 9.69** 1.85E-03
R3 4 8 1 4 2 299.39*** 4.48E-67 222 209 0.79 3.73E-01
S 125 146 2.95 8.58E-02 174 228 12.61*** 3.84E-04
T8 41 2 3 12.50*** 4.08E-04 136 148 0.91 3.39E-01
V 147 168 2.73 9.88E-02 185 148 9.47** 2.09E-03
W5 5 3 7 9.34** 2.24E-03 77 43 26.77*** 2.30E-07
Y 84 87 0.11 7.40E-01 76 74 0.07 7.98E-01
S u m2 4 1 12 4 1 1 2 4 1 12 4 1 1
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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We calculated the relative mutability of all the amino
acids as both mutant and mutated residues (Fig. 1). The
residue that had the lowest ratio of observed vs. expected
mutations (marked '1') was used as a reference in these
calculations. This residue is lysine for mutated and
alanine for mutant residues.
Among the original residues, arginine has clearly the high-
est relative mutability. The picture is completely different
for the mutant residues, where the overall relative muta-
bility among mutant residues is highest for cysteine and
tryptophan. Table 2 shows that C, D, H, K, P and W are
highly mutated residues. In the second place after arginine
in mutated residues is cysteine. Glycine and tryptophan
are also highly significantly overrepresented among
mutated residues. Proline is the only amino acid forming
a ring with the backbone and it has very rigid structure,
which bends the main chain of the protein in a character-
istic way. Proline is a known breaker of secondary struc-
tures [30]. K, E, Q, F and T are significantly
underrepresented among mutated residues.
From Table 3 can be seen that the distribution of muta-
tions in secondary structural elements is very close to that
expected based on the mutation count in the whole pro-
teins. Only S as mutated and M as mutant residue type are
significantly underrepresented. Based on the amino acid
distributions (Fig. 1) the composition of α-helices is close
to the general distribution whereas β-structures and turns
and bends have clearly different distribution. The amino
acid compositions within secondary structures are very
different. The share of α-helices is 36%, β-structures 21%
and turns and bends 21% (remaining 21% is in areas not
defined to any secondary structure type) of all the residues
in the investigated structures. The secondary structures
harbour 80% of all the disease-causing mutations. The
amino acid distribution outside the regular secondary
structural elements is very similar to whole protein except
Changes to properties of amino acids caused by mutations Figure 2
Changes to properties of amino acids caused by mutations. Average changes per residue in residue volumes when 
comparing original amino acid and mutated amino acid in A) α-helices, β-strands, turns and bends and B) separately in α-helices 
(H), 310-helices (G), extended strands (E), isolated β-bridges (B), turns (T) and bends (S). C) Average changes per residue in 
charges when comparing original amino acid and mutated amino acid in α-helices, β-strands, turns and bends and D) separately 
in α-helices, 310-helices, extended strands, isolated β-bridges, turns and bends.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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for high overrepresentation for P. The trends for mutated
and mutant residues are similar to whole proteins. R has
very high relative mutability for original residues (Fig. 1).
The only remarkable difference between Tables 2 and 4
(data calculated based on the amino acid distribution in
secondary structures) is methionine, which is highly over-
represented in Table 2 for all the mutations as a mutant
residue, but has no statistical correlation in the secondary
structures (Table 4). A, L and I appear much less fre-
quently amongst the replacing residues than expected.
Our results are in line with those published previously for
general mutation distribution [11,12].
Mutational spectrum within α-helices, β-strands and turns 
and bends
The amino acid composition in α-helices is very similar to
overall amino acid composition (Fig. 1). The only main
difference is in the ratio of glycines and prolines, which
are clearly depleted in the helices, whereas glycines, as
expected, are especially strongly overrepresented in turns
and bends. The most prominent residues in β-strands are
aliphatic isoleucine, leucine and valine followed by
alanine, phenylalanine and threonine. Aspartic acid is sur-
prisingly frequent in turns and bends.
In the analysis of helix mutations in all secondary struc-
tures [see Additional file 1] glycine is very significantly
underrepresented as mutated residue and also A and N
have statistically significant values. M is the only signifi-
cant mutant residue type. Correspondingly V, I and S have
significant chi square values as mutated residues in β-
strand, S, V and W as mutated residues [see Additional file
2]. In turns and bends the significantly mutated amino
acids are S, V, A, D, I, K and L and as mutant residues E, M,
and R [see Additional file 3].
We further investigated the mutations within these sec-
ondary structures. The distribution of disease-causing
mutations in helical structures in the investigated 44
structures is shown in Table 5. The number of mutations
in helices is altogether 928 (48%), whereas β-strand struc-
tures of extended strands and isolated β-bridges contain
550 (28%) missense mutations (Table 6) and hydrogen
bonded turns and bends contain 461 (24%) mutations
(Table 7). The results for original and mutant residues are
clearly and significantly very different for the different
structural elements. In helices, besides arginine and
cysteine other residues are not very highly mutated. If only
the secondary structures are taken into account, glycine
appears to be the most mutated residue after arginine.
This result is similar to a Steward et al. study that revealed
Table 3: Spectrum of mutations appearing in α-helix, β-strand, turn and bend structures, expected values are calculated from mutated 
and mutant amino acid composition in the studied proteinsa
Amino acid Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 148 136 1.07 3.00E-01 58 67 1.15 2.84E-01
C 54 64 1.43 2.32E-01 117 107 0.94 3.32E-01
D 81 79 0.06 8.06E-01 112 125 1.28 2.57E-01
E 96 91 0.29 5.91E-01 71 68 0.18 6.75E-01
F 53 53 0.00 9.91E-01 77 72 0.29 5.87E-01
G 220 198 2.48 1.15E-01 95 85 1.12 2.91E-01
H 63 70 0.69 4.05E-01 91 87 0.20 6.57E-01
I 83 80 0.14 7.05E-01 55 64 1.36 2.44E-01
K 43 45 0.09 7.61E-01 92 88 0.21 6.43E-01
L 188 186 0.03 8.70E-01 96 91 0.29 5.91E-01
M 6 56 30 . 0 8 7 . 7 4 E - 0 1 4 87 811.54*** 6.79E-04
N 60 72 2.12 1.46E-01 61 60 0.04 8.47E-01
P 68 76 0.76 3.82E-01 170 156 1.25 2.63E-01
Q 45 50 0.47 4.91E-01 89 92 0.13 7.17E-01
R 299 280 1.31 2.53E-01 196 179 1.71 1.91E-01
S7 8 1 0 1 5.05* 2.46E-02 144 140 0.12 7.31E-01
T 62 68 0.46 4.99E-01 119 109 0.85 3.57E-01
V 122 118 0.12 7.28E-01 138 149 0.78 3.77E-01
W 44 44 0.00 9.72E-01 56 62 0.57 4.51E-01
Y 67 68 0.00 9.46E-01 54 61 0.83 3.62E-01
S u m 1 9 3 91 9 3 9 1 9 3 91 9 3 9
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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that glycine was the second most frequently mutating
amino acid in the OMIM disease database [9].
In helices, lysine is a strongly underrepresented residue
compared with the calculated expected value. P, C, Q, W
and D show statistically significant overrepresentation
when compared to expected values, while S and L are
underrepresented among mutant amino acids. Relative
mutability in α-helices indicates that arginine is 7.29
times more mutated than expected whereas glycine is 4.88
times so.
In β-structures, R is statistically very significantly overrep-
resented and G and H have weaker enrichment. T is the
statistically least mutated residue in β-strands. Among
mutant residues, C is highly overrepresented and A under-
represented. Otherwise the results are less biased than in
helices.
R is also statistically the most overrepresented residue in
turns and bends although the χ2 score is smaller than for
the other secondary structures. G is the only other statisti-
cally highly significantly overrepresented amino acid. G is
the most flexible residue because it does not have a side
chain. It often appears in tight turns where no other resi-
due can replace it. K is highly underrepresented among
the mutated residues. Interestingly, R is the most enriched
amino acid among mutant residues.
The distributions of amino acid frequencies and relative
mutabilities in the different structural elements (Fig. 1)
are clearly very different. First of all, the values are higher
for mutated residues than for mutant residues, indicating
that the original residue in many instances is very impor-
tant and substitutions to any other residue are not possi-
ble without detrimental effects. Arginine and glycine are
among the most mutated residues in all secondary struc-
tures whereas the other amino acids have large variations
between the secondary structure types. The effect of
arginine can also be seen in the data for mutant residues.
Point mutations in arginine lead mostly to cysteine and
glutamine, which have relatively high mutability values.
The mutant residues in turns and bends have a more even
distribution than the other two elements because practi-
cally any mutation to key residues in a tight hairpin turn
leads either to the loss of hydrogen bonds or does not
allow tight turn formation and leads to consequent struc-
tural alterations.
The data for mutations outside regular elements (Table 8)
indicate that R, H and Y are significantly overrepresented
and Q, K and E underrepresented among mutated resi-
Table 4: Spectrum of mutations appearing in α-helix, β-strand, turn and bend structures. Expected values are calculated from amino 
acid composition in secondary structural elementsa
Amino acid Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 148 139 0,53 4.66E-01 58 119 31.05*** 2.51E-08
C5 4 3 2 15,50*** 6.82E-05 117 69 32.93*** 9.58E-09
D 8 19 62 , 3 4 1 . 2 6 E - 0 1 1 1 2 7 913.64*** 2.21E-04
E9 6 1 4 7 17,60*** 2.71E-05 71 69 0.04 8.33E-01
F5 3 8 7 13,51*** 2.36E-04 77 79 0.06 8.10E-01
G2 2 0 1 3 6 52,47*** 4.48E-13 95 114 3.10 7.85E-02
H6 3 4 8 5,06* 2.47E-02 91 79 1.78 1.83E-01
I8 3 1 1 0 6,51** 1.07E-02 55 104 23.00*** 1.62E-06
K4 3 1 1 3 43,42*** 4.37E-11 92 69 7.47** 6.26E-03
L 188 205 1,34 2.46E-01 96 163 27.69*** 1.42E-07
M6 5 4 9 5,02* 2.51E-02 48 45 0.27 6.02E-01
N 6 06 91 , 1 0 2 . 9 3 E - 0 1 6 17 94.16* 4.14E-02
P 6 86 70 , 0 2 8 . 9 8 E - 0 1 1 7 0 1 1 9 22.16*** 2.51E-06
Q4 58 216,87*** 3.98E-05 89 69 5.63* 1.76E-02
R2 9 9 1 1 9 272,51*** 3.43E-61 196 168 4.60* 3.19E-02
S7 8 1 0 4 6,60** 1.01E-02 144 183 8.32** 3.92E-03
T6 2 9 2 10,03** 1.53E-03 119 119 0.00 9.79E-01
V 122 144 3,33 7.01E-02 138 119 3.13 7.67E-02
W4 43 06,27** 1.23E-02 56 35 13.20*** 2.81E-04
Y 67 70 0,15 6.95E-01 54 59 0.48 4.87E-01
S u m 1 9 3 91 9 3 9 1 9 3 91 9 3 9
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Table 5: Spectrum of mutations in α-helicesa
Amino acid Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 8 98 30 . 4 5 5 . 0 3 E - 0 1 2 35 720.13*** 7.25E-06
C2 6 1 4 11.27*** 7.88E-04 56 33 15.76*** 7.18E-05
D 3 44 42 . 2 3 1 . 3 5 E - 0 1 5 93 811.78*** 5.99E-04
E6 1 9 6 12.71*** 3.64E-04 26 33 1.54 2.15E-01
F 28 36 1.76 1.84E-01 37 38 0.02 8.87E-01
G4 8 3 0 10.69*** 1.08E-03 46 54 1.31 2.52E-01
H 23 21 0.13 7.19E-01 41 38 0.26 6.12E-01
I 4 15 11 . 9 6 1 . 6 1 E - 0 1 2 95 08.63** 3.30E-03
K2 0 6 1 27.70*** 1.41E-07 52 33 10.73*** 1.05E-03
L 101 112 1.04 3.09E-01 49 78 10.86*** 9.85E-04
M4 1 2 9 5.11* 2.37E-02 24 21 0.34 5.59E-01
N 22 27 1.08 3.00E-01 29 38 2.08 1.49E-01
P 2 92 41 . 1 5 2 . 8 4 E - 0 1 9 05 719.38*** 1.07E-05
Q2 84 56.12* 1.34E-02 55 33 14.41*** 1.47E-04
R1 5 3 6 4 122.78*** 1.56E-28 73 80 0.70 4.04E-01
S 3 64 62 . 2 2 1 . 3 6 E - 0 1 5 38 813.66*** 2.19E-04
T 30 38 1.84 1.75E-01 61 57 0.31 5.79E-01
V 62 59 0.18 6.69E-01 69 57 2.61 1.06E-01
W2 41 64.19* 4.06E-02 32 17 14.36*** 1.51E-04
Y 32 33 0.01 9.29E-01 24 28 0.68 4.08E-01
Sum 928 928 928 928
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Table 6: Spectrum of mutations in β-strandsa
Amino acid Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 3 93 30 . 9 3 3 . 3 4 E - 0 1 1 43 411.49*** 6.98E-04
C1 9 1 2 4.58* 3.24E-02 39 20 19.08*** 1.26E-05
D 17 15 0.22 6.38E-01 26 22 0.56 4.54E-01
E 21 25 0.64 4.23E-01 20 20 0.01 9.36E-01
F1 5 3 6 12.66*** 3.75E-04 24 22 0.11 7.43E-01
G4 4 2 7 10.61*** 1.13E-03 27 32 0.86 3.54E-01
H2 3 1 3 8.33** 3.90E-03 32 22 4.06* 4.38E-02
I3 4 4 9 4.80* 2.84E-02 16 29 6.15** 1.31E-02
K1 3 2 3 4.60* 3.20E-02 23 20 0.57 4.49E-01
L 6 36 60 . 1 0 7 . 4 8 E - 0 1 2 74 68.05** 4.56E-03
M 14 13 0.03 8.53E-01 16 13 0.90 3.43E-01
N 19 14 1.67 1.97E-01 20 22 0.27 6.05E-01
P 1 51 11 . 0 8 2 . 9 9 E - 0 1 4 73 45.27* 2.16E-02
Q 10 16 2.24 1.34E-01 20 20 0.01 9.36E-01
R7 7 2 9 80.03*** 3.69E-19 60 48 3.17 7.50E-02
S 15 23 2.88 8.98E-02 55 52 0.18 6.68E-01
T1 6 3 5 10.20*** 1.41E-03 36 34 0.16 6.88E-01
V5 3 7 1 4.44* 3.51E-02 27 34 1.32 2.50E-01
W 16 10 3.23 7.25E-02 8 10 0.34 5.61E-01
Y 27 27 0.00 9.60E-01 13 17 0.87 3.50E-01
Sum 550 550 550 550
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Table 7: Spectrum of mutations in turns and bendsa
Amino acid Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 20 24 0.79 3.73E-01 21 28 1.85 1.74E-01
C 9 7 0.97 3.26E-01 22 16 1.86 1.72E-01
D 30 35 0.70 4.04E-01 27 19 3.56 5.92E-02
E1 4 2 7 6.28** 1.22E-02 25 16 4.43* 3.54E-02
F 10 16 2.13 1.45E-01 16 19 0.42 5.16E-01
G1 2 8 7 2 43.23*** 4.87E-11 22 27 0.94 3.32E-01
H 17 13 1.12 2.91E-01 18 19 0.04 8.51E-01
I 8 12 1.20 2.73E-01 10 25 8.75** 3.10E-03
K1 0 2 8 11.80*** 5.92E-04 17 16 0.02 8.95E-01
L 2 43 01 . 2 7 2 . 6 0 E - 0 1 2 03 99.12** 2.53E-03
M 10 8 0.67 4.13E-01 8 11 0.63 4.27E-01
N 19 26 1.72 1.90E-01 12 19 2.47 1.16E-01
P 24 29 1.02 3.12E-01 33 28 0.81 3.69E-01
Q7 2 19.71** 1.84E-03 14 16 0.37 5.44E-01
R6 9 2 6 70.17*** 5.44E-17 63 40 13.25*** 2.73E-04
S 27 34 1.27 2.59E-01 36 44 1.30 2.55E-01
T 16 20 0.68 4.09E-01 22 28 1.37 2.41E-01
V71 7 6.05** 1.39E-02 42 28 6.72** 9.52E-03
W 450 . 0 7 7 . 9 2 E - 0 1 1 6 87.33** 6.78E-03
Y 8 11 1.02 3.13E-01 17 14 0.59 4.42E-01
Sum 461 461 461 461
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Table 8: Mutated and mutant residues not in secondary structuresa
Amino acid 
group
Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
A 18 22 0.84 3.58E-01 21 29 2.16 1.42E-01
C 12 7 4.51 3.37E-02 25 17 3.93* 4.73E-02
D 46 34 4.20 4.04E-02 17 19 0.27 6.06E-01
E1 0 2 2 6.53** 1.06E-02 17 17 0.00 9.72E-01
F 15 17 0.17 6.83E-01 13 19 2.04 1.53E-01
G 35 32 0.37 5.40E-01 26 28 0.10 7.48E-01
H2 7 1 4 13.05*** 3.04E-04 24 19 1.16 2.81E-01
I 19 17 0.23 6.32E-01 16 25 3.41 6.48E-02
K1 1 2 7 9.15** 2.49E-03 13 17 0.88 3.47E-01
L 29 36 1.36 2.44E-01 43 40 0.27 6.04E-01
M 6 9 0.93 3.36E-01 13 11 0.43 5.11E-01
N1 0 2 3 6.96** 8.34E-03 30 19 5.98** 1.45E-02
P 61 52 1.44 2.29E-01 26 29 0.29 5.90E-01
Q3 2 013.97*** 1.86E-04 17 17 0.00 9.72E-01
R5 3 2 3 37.42*** 9.51E-10 49 41 1.59 2.08E-01
S 31 40 2.13 1.45E-01 47 45 0.13 7.14E-01
T 24 30 1.25 2.63E-01 22 29 1.65 1.99E-01
V 25 25 0.00 9.44E-01 25 29 0.53 4.68E-01
W 8 6 0.41 5.22E-01 11 8 0.78 3.76E-01
Y2 9 1 7 8.77** 3.06E-03 17 14 0.45 5.02E-01
Sum 472 472 472 472
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Table 9: Spectrum of mutations in α-helices in amino acid groupsa
Amino acid 
group
Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
Hydrophobic 355 348 0.13 7.19E-01 320 322 0.01 9.13E-01
Positively 
charged
95 140 14.36*** 1.51E-04 85 71 2.75 9.71E-02
Negatively 
charged
196 147 16.56*** 4.71E-05 166 152 1.39 2.39E-01
Conformatio
nal
77 54 9.96** 1.60E-03 136 111 5.50* 1.90E-02
Polar 86 118 8.70** 3.17E-03 137 159 2.94 8.62E-02
A+T 119 121 0.04 8.34E-01 84 114 7.73** 5.44E-03
Sum 928 928 928 928
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Table 10: Spectrum of mutations in β-strands in amino acid groupsa
Amino acid 
group
Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
Hydrophobic 241 285 6.72** 9.54E-03 170 191 2.27 1.32E-01
Positively 
charged
38 40 0.12 7.31E-01 46 42 0.36 5.47E-01
Negatively 
charged
113 65 35.48*** 2.58E-09 115 90 7.07** 7.82E-03
Conformatio
nal
59 39 10.86*** 9.81E-04 74 66 0.98 3.21E-01
Polar 44 53 1.62 2.03E-01 95 94 0.01 9.18E-01
A + T 5 56 82 . 5 8 1 . 0 8 E - 0 1 5 06 74.47* 3.45E-02
Sum 550 550 550 550
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Table 11: Spectrum of mutations in turns and bends in amino acid groupsa
Amino acid 
group
Original 
residues
Expected 
residues
χ2 P value Mutant 
residues
Expected 
residues
χ2 P value
Hydrophobic 80 105 6.02** 1.42E-02 151 160 0.50 4.80E-01
Positively 
charged
44 62 5.21* 2.24E-02 52 35 7.92** 4.88E-03
Negatively 
charged
96 68 11.94*** 5.48E-04 98 75 6.87** 8.78E-03
Conformatio
nal
152 102 24.95*** 5.90E-07 55 55 0.00 9.71E-01
Polar 53 81 9.44** 2.12E-03 62 79 3.58 5.85E-02
A+T 36 44 1.48 2.24E-01 43 56 3.20 7.34E-02
Sum 461 461 461 461
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid 
frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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dues while N is the only residue type that is significantly
overrepresented.
Mutational spectrum in amino acid groups within 
structural elements
Amino acids can be grouped based on their physicochem-
ical nature. The reason for performing an analysis with
residue categories is that in many sites the specific amino
acid is not very important but the suitable properties it
provides is. This can be seen e.g. in multiple sequence
alignments of protein families. We used the following six
groups: hydrophobic (V, I, L, F, M, W, Y, C), positively
charged (R, K, H), negatively charged (D and E), confor-
mational (G and P), polar (N, Q, S) and (A and T) [45].
These groups follow the amino acid substitution matrices
used for sequence alignments and database searches. The
results for amino acid frequencies in the secondary struc-
ture types are in Tables 9, 10, 11. Different groups are
over- or underrepresented in different structure types.
Negatively charged residues, due to arginine, are overrep-
resented in all three tables. Conformational residues are
also overrepresented in all three secondary structure
classes, but with varying χ2-values. Positively charged
amino acids are significantly underrepresented in helices
and overrepresented in turns and bends.
Mutations to polar residues are significantly depleted in
α-helices and especially so in turns and bends. The
number of significant observations is lower in mutant res-
idues. Negatively charged amino acids are overrepre-
sented in both β-structures and in bends and turns,
although the enrichment is relatively weak. Alanine and
threonine are underrepresented in both helices and β-
strands. These results likely reflect the importance of the
original residue. Many disease-causing mutations affect
the same positions indicating that the site is structurally or
functionally important, where any mutation disrupts the
protein activity.
Changes in amino acid volume and charge due to 
mutations
Next we examined the differences in volume and charge
between the original residue and the replacing mutant res-
idue (Fig. 2). The replacing residues within α-helices and
β-strand structures are generally physically smaller than
the original residues while in turns and bends the volume
is remarkably increased. In 310-helices the replacing resi-
due is on average 13.5 Å3 smaller than the original residue
and in α-helices almost 4 Å3 smaller. Mutations to resi-
dues in β-bridges increase the volume, while mutations in
β-strands on average reduce the volume of the amino acid.
The increase in volume in turns is 22.6 Å3 and in bends
15.8 Å3, thus on average the replacing residue is much
larger than the original residue. In turns and bends, gly-
cines form the biggest group among mutated native
amino acids. Because glycine is the smallest amino acid,
all mutations in G increase the volume of the protein. Dif-
ferences at the amino acid level show that there are clear
peaks in some residues, and that the changes in all sec-
ondary structure types are very similar (Fig. 3). Glycine
(68 Å3) is replaced by residues that are on average 85 Å3
larger in turns and bends, 83 Å3 larger in α-helices and 78
Å3 larger in β-strands. The largest residues are W, Y, F and
R. The largest amino acid, tryptophan (237 Å3) is replaced
by residues whose volume is on average 100 Å3 smaller in
β-strands and 94 Å3 and 93 Å3 smaller in α-helices and
turns and bends, respectively. Being a bulky residue, tryp-
tophan is very rare in turns and bends. In our dataset W
accounted for 1% of all residues in turns and bends. There
was just one mutated W in bends and three in turns.
Average changes in isoelectric point (IEP) are similar for
the main secondary structure types (Fig. 2C). In all the
structures the IEP is increased on average compared to the
normal structure. There are differences in the extent of the
change, the largest changes are in turns and bends – on
average close to 0.8 pI. The reason for the dramatic aver-
age increase in pI values is the introduction of prolines
and lysines that have relatively high pI values. Arginine
has the highest pI value of all amino acids, but in turns
and bends there is almost equally high enrichments of
arginines both in mutated and mutant residues, so
arginines do not affect IEP crucially. Figure 2D also shows
in detail the changes in different helices and β-structures.
The change is much larger in 310-helices than in α-helices.
A similar situation is seen for bends in which mutations
lead to clearly larger changes. Differences at the amino
acid level show that changes in charge in α-helices and β-
strand structures are minor but in turns and bends there
are clear peaks in some of the residues. C and E are
replaced by residues with lower pI values and basic K and
R by residues with higher pI values (Fig. 4).
The role of contact energies
We used RankViaContact [46] to calculate residue contact
energies for all proteins in the dataset based on three-
dimensional structures. The contact energies of the
mutated residues range from very strong -27.6 to 7.8. The
mutations are ranked based on their calculated contact
energies. A slight majority (55%) of the mutations have
strong or very strong contact energies. Most residues with
strong contact energies are important for the stability of
the protein structure. Many of the disease-related muta-
tions are thus located in crucial structural sites in which
alterations are deleterious. In figure 5A the count of con-
tact energies of the mutated residues has been calculated
in all proteins and separately for secondary structures. In
β-strand the distribution of contact energies are even, but
in other structures the distribution is biased towards weak
positive contact energies.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Figure 5B shows the contact energy distribution for muta-
tions in proteins and secondary structure types as well as
outside the secondary structural elements. The curves have
quite similar overall shapes although the location of the
peak for the maximal occurrence varies. Of note is also
that the mutation positions in turns and bends and out-
side secondary structures do not appear in sites of very
strong contacts. Mutation sites in β-structures have very
even distribution throughout the contact energy range.
We organized the residues into six groups based on their
physicochemical properties and calculated the percent-
ages of strong and weak contact energies in the groups
(Fig. 6). Among hydrophobic residues more than 90% of
the original amino acids have strong contact energies.
Polar, conformational, positively and negatively charged
mutated residues have for the most part weak contact
energies (70–85%). A and T residues have mainly strong
contact energies. These results indicate the importance of
the residue type for interactions – whether hydrophobic,
van der Waals or electronic interactions. Charged residues
often form salt bridges, while hydrophobic and aliphatic
amino acids are involved in weaker interactions. A large
proportion of mutated residues are forming interactions
which are essential for the protein and its structure. Struc-
tural alterations are the most common consequence of
disease-causing mutations [18].
Conclusion
Germline substitutions leading to the replacement of a
native residue can result in either benign effects (e.g. pol-
ymorphisms) or in genetic disease. It has been shown that
most positions in proteins can be altered without serious
effects on protein structure or function [47]. On the other
hand, the majority of disease-causing mutations have
structural effects [14]. Therefore, mutations that are phe-
notypic for disease indicate the importance for the specific
location. Knowledge of the molecular basis of mutations
is important and can be used in several ways.
Mutation spectra are clearly different for the different
structural elements. The most prominent feature for all
the elements is the strong overrepresentation of arginine
as mutated residue. Large changes in the properties of
mutant amino acids, in volume or charge, are disease-
related, but there are large differences for the structural
elements. Contact energy distributions of mutated resi-
dues are surprisingly similar except for β structures. About
half of the mutation sites are involved in strong or very
strong amino acid interactions. In conclusion, there are
many and strong trends in mutant and mutated residues.
Changes in mutations to residue charges Figure 4
Changes in mutations to residue charges. Average 
changes in mutations to residue charges in α-helices (red), β-
strands (blue), turns and bends (green). The thick line indi-
cates the original amino acid charges. Outer rings indicate 
higher charge values and inner rings lower, in steps of 1.25 pI.
Changes in mutations to residue volumes Figure 3
Changes in mutations to residue volumes. Average 
changes in mutations to residue volumes in α-helices (red), 
β-strands (blue), turns and bends (green). The thick line indi-
cates the original amino acid volumes. Outer rings indicate 
addition in volume and inner rings reduction, in steps of 35 
Å3.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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The trends are statistically significantly different for the
different secondary structures.
Previously, mutation statistics have been studied at a gen-
eral level [8,12,48] as well as a structural level [9,12], but
detailed analysis of the spectrum and effects of mutations
within secondary structural elements has been missing. In
the study of Ferrer-Costa et al. [12] the dataset consisted
of 1169 disease-associated single amino acid polymor-
phisms (daSAPs) distributed over 73 proteins with struc-
ture information from the PDB. The study combines
information from all secondary structure elements with-
out element specific data. In the study of Steward and co-
workers [9] 63 proteins contained 1292 disease-associ-
ated sites. They did not analyse secondary structures sepa-
rately. Our study involved 1939 missense mutations in
secondary structures and 2411 mutations altogether. We
localized the majority of missense mutations to α-helices.
The biggest group of daSAPs is found in coils, and helices
contain 36.7% of all daSAPs. Ferrer-Costa et al. also
included volume comparisons in their study. In contrast
to our work, the size changes to daSAPs were calculated
for the whole dataset. We calculated the changes for each
secondary structure type separately, also at amino acid
level. Arginine is the most commonly mutated residue.
The result is identical to Steward et al [9]. Wang and Moult
[18] examined 262 missense mutations in 23 proteins
and concluded that 80% of mutations destabilize the pro-
tein structure relative to the folded state based on changes
in hydrophobic burial, backbone strain, overpacking, and
electrostatic interactions. In several other studies, struc-
tural properties have been combined with a sequence pro-
file for the mutated position [21,23,49], which reflects the
occurrence of other amino acid types at corresponding
sites in homologous proteins.
Vitkup et al. [11] investigated in total, 4236 mutations
from 436 genes and concluded that mutations at arginine
and glycine residues are together responsible for about
30% of genetic diseases. This result is similar to ours. In
our dataset, 25% of all missense mutations occur in R and
G, and 23% are present in the examined secondary struc-
tures. Vitkup et al. also found that random mutations at
tryptophan and cysteine have the highest probability of
causing disease, which is in line with our results. The over-
all relative mutability to mutant residues is 3.46 for C and
3.31 for W compared to alanine which has the lowest ratio
of observed vs. expected mutations and is considered as 1.
To correlate the mutated and mutant types to protein
structures it is important to know at which secondary
structural element the alteration appears. Protein function
and interactions require both stability and specificity. Pro-
teins fold according to the minimum free energy. In con-
trast, they organize themselves to recognize a transition
state or a ligand [50]. Amino acids and mutations have
very distinct differences in the frequencies in the second-
ary structural elements. Multiple sequence alignments can
be used to investigate allowed substitutions in protein
families. Our analysis revealed mutation types which are
most likely deleterious. This information could also be
used for the development and optimization of amino acid
comparison tables for individual secondary structural ele-
ments. Our data could also add to the reliability of the
predictions of mutation effects.
Distribution of contact energies for mutated amino acids Figure 5
Distribution of contact energies for mutated amino 
acids. The energies were calculated with the RankViaCon-
tact program. A) Data for all mutations, and B) distribution in 
secondary structural elements α-helices (red), β-strands 
(blue), turns and bends (green), outside secondary structures 
(yellow), and whole proteins (black).BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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Methods
We investigated proteins for which numerous disease-
causing missense mutations were available along with an
experimentally defined three-dimensional structure.
Mutation data was collected from BTKbase [51-53] for Btk
mutations, CD40Lbase [54-56] for CD40L mutations and
from Human Gene Mutation Database (HGMD) [6] for
the remainder. The publicly available mutations are in the
supplementary table 4 [see Additional file 4], full list is
available from authors by request. The DSSP program [57]
was used to identify secondary structures for three helix
types, two extended β-strand types, turns and bends,
based on the stereochemistry of the protein structure. The
DSSP program was used to systematically assign second-
ary structures for each residue in the three-dimensional
structures obtained from the Protein Data Bank (PDB)
[58]. A Perl script was written to connect mutation infor-
mation to protein structure data (dssp files).
If more than one structure existed for a protein or a pro-
tein domain, the one with the highest resolution and the
longest chain length was chosen. All data was stored in a
mySQL database. Altogether we investigated 44 proteins
with a total of 12540 residues, of which 9878 were in the
examined secondary structures. The proteins contained
2411 different disease-causing mutations, 1939 present in
secondary structures.
The RankViaContact service was used to calculate residue-
residue contact energies based on a coarse-grained model
[46]. The energy parameters used for residue-residue con-
tacts [59] were derived considering the secondary struc-
tural environments. The contact energies were estimated
for all the missense mutations located in the secondary
structures.
Mutation statistics were analysed by comparing the fre-
quencies of the obtained mutations with the expected val-
ues. Expected values for mutated residues within α-
helices, β-strands and turns and bends were calculated
using the distribution of all amino acids in respective sec-
ondary structure. In the case of the mutant amino acids
within different secondary structures, the expected values
were calculated from codon diversity by taking into
account all possible amino acid substitutions. In order to
reveal how the mutation distribution in secondary struc-
tures compares to the overall distribution of mutations in
the dataset, the expectation values for mutated and
mutant residues were calculated based on all the muta-
tions in secondary structures.
Mutant residues with strong and weak contact energies Figure 6
Mutant residues with strong and weak contact energies. The percentage of mutant residues with strong (black) and 
weak (white) contact energies in physicochemical amino acid groups.BMC Structural Biology 2007, 7:56 http://www.biomedcentral.com/1472-6807/7/56
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The χ2 test was used to determine the significance of the
results. Chi square values were calculated using the fol-
lowing formula:
where fo is the observed frequency and fe is the expected
frequency for an amino acid. P-values and 95% confi-
dence intervals were estimated in one-tailed fashion. Rel-
ative mutability was calculated using the formula:
where  N'  is the least mutated residue type that was
obtained by calculating the ratio between observed and
expected value. N represents the number of mutated orig-
inal or mutant residues for an amino acid type. The rela-
tive mutability was calculated for each residue type in all
the investigated secondary structural elements.
In order to calculate changes in the isoelectric point we
used the Emboss iep program [60] to predict IEPs for
native and mutant proteins. The average change in IEP in
each secondary structure type was calculated. The changes
in residue volumes in different secondary structure types
were obtained by using residue volumes [61]. The results
were weighted by the amount of individual mutations
and averaged by the number of mutant residues in respec-
tive secondary structures.
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